Important Investigation for Altimmune Investors
Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating potential claims involving investors of Altimmune, Inc. The firm urges anyone who suffered significant financial losses in Altimmune to come forward. The focus is on those whose losses exceed $75,000.
What Investors Need to Know
The investigation arises from a recent press release issued by Altimmune that revealed disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide. Despite expectations, the company failed to meet statistical significance in the primary endpoint of its analysis, which evaluated fibrosis reduction. This news has prompted serious inquiries into the company's management and their previous statements.
Legal Options Available
If you are an investor impacted by this decline, it is crucial to understand your legal rights. You can connect directly with James (Josh) Wilson, a partner at the firm, to discuss your options and the potential for joining the class action. Faruqi & Faruqi is specifically seeking individuals wanting to become lead plaintiffs in the case.
Understanding The Impact of Recent Developments
On the day following the announcement regarding the trial results, Altimmune's stock price plummeted from $7.71 to $3.61, marking a dramatic 53.2% drop in a single day. This significant decline has raised concerns among investors, prompting the legal investigation.
Who Can Serve as Lead Plaintiff?
In class action settlements, the lead plaintiff is typically the member with the largest financial stake who also adequately represents other class members. Those affected can apply to be considered for this role or choose to remain a passive member of the class. Regardless of participation in this capacity, all members maintain the ability to recover losses.
Faruqi & Faruqi’s Commitment
With decades of experience, Faruqi & Faruqi, LLP has successfully recovered substantial amounts for investors. Since its inception in 1995, the firm has proven its dedication to holding companies accountable for their actions. Investors are encouraged to reach out with information related to Altimmune or the situation surrounding that company, including insights from current and former employees.
Next Steps for Affected Investors
Investors who wish to learn more about the situation with Altimmune or who want to engage with the class action can contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm prides itself on handling communications confidentially and providing personalized support.
Frequently Asked Questions
What is the investigation about?
The investigation is focused on potential claims against Altimmune, Inc. following disappointing trial results that significantly impacted the stock price.
Who can join the class action?
Any investor who experienced losses exceeding $75,000 in Altimmune can consider joining the class action.
What should I do if I qualify?
Contact Faruqi & Faruqi, LLP directly to discuss your options and potential involvement as a lead plaintiff.
How can I protect my investment?
Staying informed about developments and exploring legal options with the help of experienced lawyers can help protect your investment.
Can I remain anonymous?
Yes, you can choose to remain a passive member of the class without engaging as a lead plaintiff, maintaining your option for recovery.
